Riancho JA, Peris P, González-Macías J, Pérez-Castrillón JL. Executive summary clinicalpractice guideline of postmenopausal, glucocortcioid-induced and male osteoporosis (2022update). Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM). Rev Osteoporos Metab Miner 2022;14:13-33
DOI: 10.4321/S1889-836X2022000100003
Cosman F, Lewiecki EM, Eastell R et al. Goal-directed osteoporosis treatment:ASBMR/BHOF task force position statement 2024. J Bone Miner Res , 2024, 39, 1393–1405
DOI: 10.1093/jbmr/zjae119
Geusens P, Van den Bergh J, Roux C et al. The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture. Cur Osteoporos Rep 2024; 22:611–620
DOI: 10.1007/s11914-024-00885-z
Schini T, Lui LY, Vilaca T et al. The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project. J Bone Miner Res 2025; 40: 307-314
DOI: 10.1093/jbmr/zjae201
Mateo J , Usategui-Martín R , Torres AM et al. Improving prediction of fragility fractures in postmenopausal women using random forest. Comp Biol Med 2025; 196: 110666
DOI: 10.1016/j.compbiomed.2025.110666
Papapoulos S, Makras P. Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future. Pharmaceuticals 2025, 18, 1068
DOI: 10.3390/ph18071068
Freemantle N, S. Satram-Hoang S , E.-T. Tang ET et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012; 23: 317-326
DOI: 10.1007/s00198-011-1780-1
Kumar S , Wang M , Kim AS , Center JR, McDonald MM, Girgis CM Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fracture. J Bone Miner Res 2025,40: 1017-1034
DOI: 10.1093/jbmr/zjaf037
Geusens P, Marin F, Kendler DL et al Effects of teriparatide compared with risedronate on the risk of fractures in subgroupes of postmenopausal women with severe osteoporosis: The Vero trial. J Bone Miner Res 2018; 33: 783-794
DOI: 10.1002/jbmr.3384
Han YX, Ma YY, Wu HX et al. Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis randomised controlled trials. EClinicalMedicine 2024; 68:102425.
DOI: 10.1016/j.eclinm.2024.102425